IL2 and melanoma: Although there were no significant differences in OS between the two groups, the PFS of IL-2 and Ziv-Aflibercept group significantly improved compared with IL-2 alone group, suggesting that anti-VEGF combined with immunosuppressive agents might be an excellent therapeutic option for patients with melanoma.